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Abstract Aim of the review To review the consequences
of drug-related problems (DRP) in systemic cancer therapy
and identify speciﬁc contributions of the pharmacist to
minimise treatment-associated risks. Method Searches in
PubMed, Embase and the Cochrane Library were con-
ducted. Bibliographies of retrieved articles were examined
for additional references. Only papers in English between
1980 and 2007 were included. Results In systemic cancer
therapy there is an enormous potential for DRP due to the
high toxicity and the complexity of most therapeutic reg-
imens. The most frequently reported DRP can be classiﬁed
into adverse effects, drug–drug interactions, medication
errors, and non-adherence. Pharmacists have enhanced
efforts to assure quality and safety in systemic cancer
therapy together with other health care providers. In con-
sequence, oncology pharmacy has evolved as a novel
specialist discipline. The endeavour to merge and co-
ordinate individual activities and services of the pharmacist
has led to pharmaceutical care concepts which aim at
offering novel solutions to the various DRP. Conclusion
Pharmaceutical care for cancer patients should be devel-
oped within research projects and integrated into disease
management programs in order to ensure broad
implementation.
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Impact of ﬁndings on practice
• There is an enormous potential for drug-related prob-
lems in cancer therapy
• The most frequently reported drug-related problems in
systemic cancer therapy are adverse effects, drug–drug
interactions, medication errors, and non-adherence
• Pharmacists can contribute substantially to risk mini-
misation in systemic cancer therapy by adding speciﬁc
drug-related knowledge to the treatment team and
offering patient-related services
• Pharmaceutical care for cancer patients offers novel
solutions to the various drug-related problems and
should be further developed in research projects
Introduction
In systemic cancer therapy, drug regimens are administered
following established protocols which have been carefully
evaluated in clinical trials. The administration of support-
ive medication is not as standardised as with antineoplastic
therapy. Major components of the supportive therapy are
selected by the general practitioners or the patients them-
selves rather than by the oncologist. Furthermore, patients
tend to see more than one physician involved in the cancer
care process as well as alternative practitioners. Patients
are also exposed to a tremendous variety of drugs which
are available to the customer without prescription (over-
the-counter, OTC).
The more complex drug therapy is, the higher the risk of
experiencing drug-related problems (DRP) such as adverse
effects, interactions, medication errors, and non-adherence.
Drug-related problems in cancer chemotherapy can have
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narrow therapeutic range of anticancer drugs. The tragic
case of Betsy Lehman who died from an overdose of
cyclophosphamide at the Dana Faber Cancer Center in
Boston demonstrated this risk painfully [1]. It must be the
goal of all health care providers to minimise treatment-
associated risks as much as possible.
Over the last few decades the pharmacy profession has
experienced a change from traditional drug-oriented
toward patient-oriented services. In oncology, pharmacists
have established central services for compounding cyto-
toxic drugs and started to offer industry-independent drug
information for physicians and patients as well as thera-
peutic drug monitoring for critical dose drugs, e.g.
aminoglycosides in neutropenic patients. As the specialist
knowledge of pharmacists in this ﬁeld has increased con-
tinuously ‘‘oncology pharmacy’’ has evolved into a new
pharmaceutical discipline with its own curriculum. In 1995
the International Society for Oncology Pharmacy Practi-
tioners (ISOPP) was founded. The aim of the society is ‘‘to
determine the optimal medical treatment for cancer
patients, thereby improving their quality of life’’. Cur-
rently, the concept of pharmaceutical care is being adapted
to the needs of the cancer patient as a further step to
optimising individual drug therapy [2].
The intention of this review is to summarise possible
solutions for DRP in oncology focussing on the speciﬁc
tasks of the pharmacist.
Aim of the review
It was the aim of this article to review and analyse the most
frequent DRP and their consequences in systemic cancer
therapy. Moreover, speciﬁc contributions of the pharmacist
to minimise treatment-associated risks should be identiﬁed.
Method
Searches in PubMed, Embase and the Cochrane Library
were conducted. Database terms included DRP, adverse
effects, drug–drug interactions, medication errors, adher-
ence, compliance, pharmaceutical care in connection with
oncology or cancer. Bibliographies of retrieved articles
were examined for additional references. Only papers in
English between 1980 and 2007 were included.
Results
Various DRP can occur in the treatment path of systemic
cancer therapy (Table 1). In a recently published study
conducted on an oncology ward of a Swedish hospital 114
DRP in 58 patients were identiﬁed indicating their high
incidence in cancer patients [3]. In this section, major
problems related to adverse effects, drug–drug interactions,
medication errors, and non-adherence are reviewed
separately.
Adverse effects
According to the World Health Organization (WHO) an
adverse drug reaction (ADR) is deﬁned as a response to a
drug which is noxious and unintended, and which occurs at
doses normally used or tested in man for prophylaxis,
diagnosis or therapy of disease. In cancer chemotherapy
such ADRs are strongly connected to the treatment itself.
Because of the fact that most cytotoxic agents cannot dis-
tinguish between normal and neoplastic cells, most ADRs
seem to be unavoidable. They are often accepted not only
by patients but also by health care providers.
In order to illustrate the most common ADRs in
oncology patients in a cancer centre in Australia were
observed and the incidence as well as the predictability,
preventability, and severity of the occurred ADRs were
assessed. Among the ten most common ADRs constipation
ranked ﬁrst but was connected directly to the use of opioids
rather than to cytotoxic chemotherapy. Nausea and vom-
iting, fatigue, alopecia, drowsiness and myelosuppression
ranked second to sixth. Of these ADRs 88% were pre-
dictable and about 50% even probably preventable,
because of inadequate use of preventative measures [4].
As well as the incidence of ADRs in modern chemo-
therapy the patients’ perceptions of the impact of these
ADRs on well being and quality of life are increasingly
taken into account. Patient perceptions have changed
markedly over the last two decades. Whereas in 1983
physical symptoms such as nausea, vomiting and hair loss
were most troubling from the patients’ point of view, in
2002 psychosocial complaints ranked among the top ten
symptoms, with the complaint ‘‘affects my family or
partner’’ rated as the most severe ADR. Alopecia and
fatigue ranked second and third place [5, 6].
Table 1 Drug-related problems can originate from several steps of the
treatment path
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become a focus of clinical research and new drugs such as
aprepitant, a neurokinin-1-receptor antagonist for the pre-
vention of nausea and vomiting, were developed [7].
Despite these new therapeutic options the minimisation of
toxic effects of chemotherapy still seems to be a chal-
lenging task.
The ﬁrst and most important step to a better manage-
ment of ADRs is the formulation and implementation of
evidence-based clinical practice guidelines for the different
symptoms in a multidisciplinary approach. Several studies
have shown a positive effect of guidelines for antiemetic
prophylaxis and therapy on both clinical and economic
outcomes [8–11]. The most important inﬂuencing factors
seem to be the appropriate use of 5-HT3 receptor antago-
nists and the application of oral drug formulations.
Nevertheless, altering the usage patterns of physicians to
comply with evidence-based guidelines seems to be difﬁ-
cult. Methods such as the use of computerised decision
support systems and educational outreach mechanisms
appear to be most effective particularly when used in
combination [12]. The pharmacist can support and promote
the adherence to guidelines [13].
A second step to a better management of ADRs is the
implementation of standardised chemotherapy order forms
that also contain supportive care medication. By using
standardised order forms a more appropriate prescribing of
antiemetics based on the level of emetogenicity of
administered chemotherapy and thus a reduction in drug
expenditure can be achieved [14]. Such order forms should
be elaborated following a multidisciplinary approach
including physicians, pharmacists and nurses.
Drug–drug interactions
The large number of prescribed drugs administered to
cancer patients leads to a high potential for drug–drug
interactions. As indicated previously many cancer patients
also use over-the-counter medication as well as alternative
and complementary treatment options. Frequently, cancer
patients suffer from concomitant chronic diseases that
require the intake of other drugs, further increasing the risk
of interactions. This problem is often underestimated in
oncology as highlighted in several review articles [15–18].
Moreover, drug–food, drug–disease and drug–diagnostics
interactions have to be considered that are, however,
beyond the scope of this article.
Drug–drug interactions must be avoided as they can lead
to overdosing or underdosing of anticancer drugs with the
consequence of toxicity or a loss of effectiveness, respec-
tively. However, not all published interactions are also
clinically relevant. A rational and safe drug therapy
includes a check for potential drug–drug interactions based
on the individual medication and a decision whether and
how identiﬁed drug–drug interactions have to be consid-
ered or not.
Knowledge of the mechanisms of interactions is crucial
to assess the clinical relevance of an interaction. Drug–drug
interactions are usually classiﬁed as pharmaceutical,
pharmacokinetic or pharmacodynamic interactions
(Table 2). The risk of interactions can differ substantially
between individual drugs, even within the same class of
drugs. This can be considered when selecting a particular
drug for an individual patient.
For some drugs with a high potential for interactions,
therapeutic drug monitoring can be useful to detect and
control interactions. The advantage of this approach is that
the dosage of the drug of risk can be adapted to the mea-
sured individual plasma concentrations. Thus the treatment
of both interacting drugs may be continued. Examples are
anticonvulsant, antidepressant and antifungal drugs which
are often administered to cancer patients as supportive
medication [19].
In general, it is almost impossible for the physician to
keep in mind all of the interaction mechanisms and
potential consequences for the individual patient. Regular
interaction checks by the pharmacist may solve this prob-
lem as he is the only health care professional who may
have an overview of the drugs prescribed by various phy-
sicians and the medication taken by the patient on his own
initiative. The avoidance of drug–drug interactions should
be regarded as a multidisciplinary task [20].
The basis for each interaction check is to take the
medication history of each patient and to update it regu-
larly. Nowadays software tools are available facilitating
rapid interaction checks and providing information on the
mechanism and clinical relevance of an interaction. Each
hospital and community pharmacy should have access to at
least one of these tools.
Table 2 Classiﬁcation of drug–drug interactions
Pharmaceutical interactions
Mostly physical or chemical incompatibilities, e.g. chemical reactions
or precipitations due to drug admixtures.
Pharmacokinetic interactions
Occur at the level of drug absorption, distribution, excretion, and
metabolism. Frequently, the cytochrome P450 metabolising
enzyme system and drug transporters such as P-glycoprotein are
involved in such interactions.
Pharmacodynamic interactions
Directly related to the desired or undesired drug effects, e.g. the
antitumoral effect or drug-associated toxicity.
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In addition to the DRP described above, there are numerous
risks for the occurrence of medication errors along the
therapeutic path in oncology. A medication error is deﬁned
as any preventable event that may cause or lead to inap-
propriate medication use or patient harm, while the
medication is in the control of the health care professional,
patient, or consumer [21]. In 2000 the American Institute
of Medicine published their report ‘‘To err is human:
Building a Safer Health System’’ which analysed ﬂaws in
the health system and offered suggestions for its
improvement [22]. Based on the results of a study con-
ducted in Utah and Colorado in 1992 an incidence of about
3% adverse events in hospitalised patients was found, of
which the majority of the non-operative events were
adverse drug events (ADE) [23]. The authors concluded
that iatrogenic injury continues to be a signiﬁcant public
health problem. Due to the narrow therapeutic range of
many anticancer drugs, the impact of an ADE is more
serious (and at worst lethal) compared to other systemically
administered drugs. Antineoplastic agents were found to be
the second most common group of drugs which caused
lethal medication errors [24]. As well as quality and safety
issues, the reduction of medication errors has a ﬁnancial
effect.
The ﬁrst source of medication errors is the prescription
and ordering process: the wrong protocol may be chosen,
the cumulative dose may be mixed up with the single dose,
the route of administration may not be clearly indicated or
misinterpretation of the physicians’ handwriting may lead
to errors. A study carried out in a cytotoxic preparation unit
in a French hospital revealed in only a 6 month period
more than 300 medication errors out of 1,262 prescriptions
for 285 patients. Most errors ([70%) were found to be
simple physicochemical incompatibilities, e.g. incompati-
bility of the drug with the used matrix. However, also over-
and underdosage as well as wrong medications were
identiﬁed [25]. The authors conclude that most of these
errors could possibly be avoided by a computerised pre-
scription network. Computer-assisted solutions enable
physicians to order the medication electronically which is
nowadays one way to reduce the incidence of those errors.
Mekhjian et al. evaluated the beneﬁts of physician order
entry systems and found that transcription errors could be
reduced and speed in the ordering process could be
improved. Even the duration of the stay in hospital could
be reduced by the system [26]. Particularly in oncology, the
computerised physician order entry (CPOE) has obvious
advantages. A recent study has shown that CPOE in elec-
tronic medical records improves completeness of the
medical record compared to paper charts independent of
regimen complexity [27]. Prepared protocols facilitate
correct ordering and double checking by the programme
itself and by the pharmacist responsible. In addition, sup-
portive medication, such as hydration or the antiemetic or
antiallergic medication can be automatically proposed
depending on the selected regimen. Moreover, the risk of
misinterpretation of handwriting is eliminated. Recently, a
CPOE system with integrated clinical decision support has
been implemented in Ontario (Canada). This system, for
example, alerts the clinician when maximum cumulative
doses are reached, calculates body surface area, and esti-
mates the creatinine clearance of the patient [28]. With all
the advantages of these systems it has to be taken into
account that new risks may arise from those new processes
such as information errors due to the lack of clearness on
the monitor [29].
The next step after ordering, the compounding of cyto-
toxic drugs also holds various risks, especially when
performed on the ward. The implementation of central
cytotoxic preparation units in pharmacy departments in the
late 1980s has been one of the ﬁrst measures to standardise
the process in order to increase safety. Nevertheless, of
30,819 preparations surveyed in a study on incidence and
risk factors of preparation errors 140 were found to be
defective (0.45%) [30]. Less than half of those cases were
classiﬁed as major errors including wrong dosage, wrong
labelling or the use of incompatible diluents. Although the
incidence is fairly low it must still be the aim to reduce this
further by analysing the risk factors such as workload.
Centralisation itself offers many more options for safety
improvement. Standardised pharmaceutical validation
leads to an increased interception of medication errors in
antineoplastic treatment. This can be explained by the
improved knowledge of the pharmacists involved in the
validation process. In consequence of a standardised
pharmaceutical validation process in the hematology–
oncology department of a 550-bed university hospital the
number of detected medication errors that did not reach the
patients could be increased by 41% (from 14.08 medica-
tion errors/1,000 patient days to 19.83 medication errors/
1,000 patient days) in the second year after the introduction
of pharmacists in the multidisciplinary oncology team [31].
Using their expertise, pharmacists can facilitate protocol
development and adherence, dose veriﬁcations and edu-
cation of other health care practitioners [32].
Finally, storage and administration errors of cytotoxic
drugs form a group of major medication errors with serious
consequences for the patient. Therefore, it is mandatory
that the assigned staff are well trained in all aspects of
chemotherapy storage and administration. For many drugs,
special storage conditions, e.g. refrigeration or protection
from light, have to be considered. Detailed knowledge of
the administered drugs is also very important in order to
educate the patient and to react appropriately when
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asation the necessary measures have to be initiated.
Different drugs require different measures which the on-
cologically trained staff needs to know. An extravasation
kit including essential items for ﬁrst aid must be made
available on site [33]. Incorrect or delayed treatment can
cause serious damage to the patient, resulting in even the
loss of a limb.
Various surveys have been undertaken in order to ﬁnd
solutions for the prevention of medication errors. The non-
punitive reporting of errors is a necessary requirement to be
able to detect, analyse and consequently minimise the
incidence and severity of medication errors in oncology.
Safety measures with error reporting and analysis have
been developed and implemented in order to improve the
entire system [34]. The most effective improvements of
treatment performance have been achieved by multidisci-
plinary system approaches integrating physicians,
pharmacists and nurses [2, 32, 34–36].
Non-adherence
Adherence (or compliance) is generally deﬁned as the
extent to which a person’s behaviour, taking medication,
following a diet, and/or executing lifestyle changes, cor-
responds with agreed recommendations from a health
care provider [37]. Non-adherence strongly compromises
the success of a patient’s therapy, results in additional,
potentially unnecessary, diagnostic and therapeutic pro-
cedures and thus generates further costs and possibly
health problems as a consequence of the treatments
themselves. It is important to note that the traditional
concept that patients are solely responsible for taking
their medication (and therefore non-adherence is a
patient-driven problem) is misleading. The WHO under-
stands adherence as a phenomenon consisting of ﬁve
dimensions (Table 3). The magnitude of this problem is
further emphasised by the fact that adherence rates for
many long-term drug therapies range from only 40 to
78% [38, 39].
It is a difﬁcult task to assess patient adherence reliably.
Patient self-reports, rates of prescription reﬁlls, patient
diaries or pill counts as the sole basis for the measurement
of adherence have been shown to be inadequate [38–40]. It
has been demonstrated that these methods overestimate the
degree to which patients adhere to their tamoxifen regimen
[40]. The use of microelectronic adherence monitoring
(Medication Event Monitoring System, MEMS
TM, Fig. 1)
provides a valuable estimate of the timing of events and
insights into patients’ behaviour in taking medication.
However, to prove actual intake of the medication,
additional plasma concentration monitoring would be
necessary. To obtain an optimal measurement of patient
adherence, a combination of several methods is suggested
[38].
Studies conducted in various disease areas have shown
that a wide variety of methods to improve adherence is
available. A recently published review classiﬁes these
methods into four general categories: patient education,
improved dosage, increased hours when clinics are open,
and improved communication between health care pro-
viders and patients [38]. All four categories require a
collaborative approach including all members of the mul-
tidisciplinary health care team. Due to their position in the
chain of health care providers, this requires the contribution
of pharmacists, not only in the hospital setting but also in
community pharmacies [41]. It has been shown that no
single intervention strategy appears consistently more
effective than another. Successful methods are complex
and comprehensive as well as labour-intensive [38, 42].
The Cochrane Review on Interventions to Enhance
Medication Adherence concludes that there is no evidence
that low adherence can be ‘‘cured’’ and hence efforts to
improve adherence must be maintained for as long as the
treatment is needed [43].
Cancer patients seem to beneﬁt especially from inter-
ventions towards an optimised adherence, resulting in
improved outcomes [42]. Research investigating adherence
in oncology settings has been mostly focussed on palliative
care and supportive medication because chemotherapy has
mainly been administered intravenously in hospitals or
Table 3 The ﬁve dimensions of adherence and examples of associated factors (adapted from [34])
Social/economic factors Health care team/system-related
factors
Condition-related factors Therapy-related factors Patient-related factors
Economic status Patient-provider relationship Severity of symptoms Complexity of regimen Anxiety about side effects
Cultural beliefs Education of providers Level of disability Treatment duration Patients’ motivation
Illiteracy Capacity of system Rate of progression Changes in treatment Patients’ expectations
Age Duration of consultations Co-morbidities Side effects Forgetfulness
Distance from treatment
center
Medication distribution system Availability of effective
treatments
Previous treatment
failures
Patients’ knowledge
about illness
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importance of oral anticancer drugs such as capecitabine,
etoposide, vinorelbine, erlotinib and sorafenib, patients
increasingly take over the responsibility for the correct
administration of their prescribed therapy. Although cancer
patients might be more adherent than other patient groups
due to a high level of motivation, the slightest non-adher-
ence can endanger the therapeutic goals [39].
Only few studies have been published investigating the
level of adherence of cancer patients. In a cohort of out-
patients receiving chemotherapy for haematologic
malignancies adherence to the allopurinol and prednisolone
prescription was measured based on plasma concentrations.
It was shown that control patients without intervention
were adherent only 17% of the time with allopurinol and
27% of the time with prednisone. Three specially devel-
oped intervention packages including education and home
visits resulted in increased adherence rates of 44–48% and
33–38% of the time for allopurinol and prednisone,
respectively [44]. Another study assessed adherence in
patients with breast cancer receiving oral cyclophospha-
mide and found that 43% of the patient population met
criteria for non-adherence according to both behavioural
and dosage deﬁnitions [45]. In a recently published study in
a cohort of 2816 women adherence to tamoxifen treatment
was investigated using prescription reﬁll data: 22.1% of the
patients exhibited a discontinuation of treatment (non-
persistence) within 1 year [46]. An open controlled trial is
currently undertaken at the University of Bonn investigat-
ing the impact of intensiﬁed pharmaceutical care provision
on the adherence of patients receiving oral capecitabine
using the MEMS
TM-technology. Pharmacists’ interventions
include the extensive provision of drug information to the
patients and health care professionals, routine checks for
drug interactions, preparation of written drug intake plans
for patients, regular pharmacist consultations and struc-
tured documentation of the pharmaceutical care process
[47].
Discussion
The recognition of the described risks of the individual
patient associated with complex drug therapies has led to
the development of a conceptual framework for an
advanced pharmacy practice philosophy. The concept of
pharmaceutical care was introduced as a further develop-
ment of the pharmaceutical profession gaining acceptance
in Europe and worldwide [48, 49]. The American Society
of Health System Pharmacists set up guidelines for stan-
dardised pharmaceutical care to ensure that pharmacists
practicing pharmaceutical care work to the same standard
[50].
Patients with complex drug regimens and/or chronic
diseases and those who frequently need to be hospitalised
might beneﬁt from pharmaceutical care in particular. These
criteria apply to many cancer patients. Within the phar-
maceutical care process the application of agreed
therapeutic algorithms can be assured on the individual
basis. The adherence of the patient can be improved by
patient education before and during the treatment cycles
combined with patient counselling regarding drug therapy,
adverse effects and complementary treatment options.
The London oncology pharmacy group introduced
guidelines for pharmaceutical care of cancer patients which
not only include the actual ‘pharmaceutical care’ as such,
but standardise the clinical pharmacy activities, dispensing,
updating therapeutic policies, cytotoxic reconstitution,
drug information, clinical trials, and the oncology training
of pharmacists [51]. A group of British experts has drawn
up a policy framework for commissioning cancer services.
They suggest the establishment of structures which support
the seamless care of cancer patients in the community
setting in a network of all parties in order to make use of
the respective specialist knowledge [52]. Accordingly,
information ﬂow at discharge from hospital to the com-
munity should be optimised utilising pharmaceutical care
plans to ensure the efﬁcient distribution of medication to
the patient is not interrupted.
Although there are some reports on the implementation
of pharmaceutical care for cancer patients there is still little
scientiﬁc evidence on the feasibility of pharmaceutical care
and its actual beneﬁt to the patient. In Canada, projects
have been carried out which suggest to implement suitable
outcome parameters to evaluate the impact of pharma-
ceutical services in oncology [53]. These have stimulated a
wide discussion in Canadian health care politics regarding
the necessity of the services offered. In Scotland, research
Fig. 1 Medication event monitoring system, MEMS
TM: The pill
bottle cap contains a micro-electronic circuit that registers when the
bottle is opened. This data may then be transferred to a computer via a
reading device
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dardisation of the provision of pharmaceutical care to
cancer patients [54]. In Germany, various research projects
are being carried out which investigate the feasibility and
beneﬁt of pharmaceutical care for patients with different
indications. Patients with breast and colorectal cancer as
well as patients receiving oral chemotherapy are the focus
of projects at the University of Bonn. Another project is
being carried out in Hamburg developing the provision of
pharmaceutical care to lung cancer patients [2].
In terms of cancer many disciplines contribute to the care
process. Thus, cross-profession and cross-sector coopera-
tioniscrucialinordertoimproveinformationﬂow.Overthe
last few years disease management programs (DMPs) have
increasinglybeenintroducedtocoverthewholecareprocess
which begins with the early diagnosis of the disease. They
aim at providing the optimal medical care by the imple-
mentation of evidence-based guidelines. Pharmaceutical
care concepts seem to have the potential to support the goals
of DMPs and could be easily integrated in programmes for
cancer patients. However, it is necessary to document the
impact of pharmaceutical care on patient outcomes in
order to comply with the demand for transparency.
Conclusions
Systemic cancer therapy is particularly complex and hence
associated with multiple risks for the patient as described
above. Many of these risks are preventable by speciﬁc
measures which can be taken by a particular health care
provider or the patient. The pharmacist with his central
position relating to drug dispensing and utilisation can
contribute substantially by adding speciﬁc drug-related
knowledge and offering patient-related services.
Pharmaceutical care is designed as a framework that
integrates individual contributions of the pharmacist into
the entire therapeutic path. Model projects are urgently
needed to assess the clinical, humanistic and economic
outcome of patient-oriented pharmaceutical services. The
integration of pharmaceutical care into disease manage-
ment programmes might facilitate efﬁcient collaboration
between all health care professionals and hence improve
effectiveness and safety of systemic cancer therapy.
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